Genetic variants in the candidate genes of the apoptosis pathway and susceptibility to chronic myeloid leukemia

Blood

Volumn 113, Issue 11, 2009, Pages 2517-2525

  Kim, Dong Hwan Dennis ^a,b   Xu, Wei ^a   Clement, Ma ^a   Liu, Xiangdong ^c   Siminovitch, Katherine ^c   Messner, Hans A ^a   Lipton, Jeffrey H ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b Sungkyunkwan University School of Medicine   (South Korea)

^c UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; CARRIER PROTEIN; CASPASE 7; CD135 ANTIGEN; CYTOCHROME P450 3A5; FOCAL ADHESION KINASE 1; G PROTEIN BETA POLYPEPTIDE 3; GAMMA INTERFERON; GAMMA INTERFERON RECEPTOR; GAMMA INTERFERON RECEPTOR 1; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMATINIB; INTERFERON; INTERFERON GAMMA RECEPTOR 2; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1 RECEPTOR TYPE I; INTERLEUKIN 1BETA; JANUS KINASE 3; MEMBRANE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; OROSOMUCOID; PROTEIN BCL 2; PROTEIN HOCT1; SOLUTE CARRIER FAMILY 22 MEMBER 1; TUMOR MARKER; UNC 51 LIKE KINASE 3; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN A; WT1 PROTEIN;

ADULT; AGED; ALLELE; ANGIOGENESIS; APOPTOSIS; ARTICLE; BONE MARROW CELL; BONE MARROW TRANSPLANTATION; CANCER GROWTH; CANCER RISK; CANCER SUSCEPTIBILITY; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENE IDENTIFICATION; GENETIC VARIABILITY; HAPLOTYPE; HUMAN; HUMAN CELL; LEUKEMOGENESIS; MAJOR CLINICAL STUDY; MALE; ONCOGENE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; XENOBIOTIC METABOLISM;

EID: 63849213065     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-07-169110     Document Type: Article

References (44)

1. Bose S, Deininger M, Gora-Tybor J, Goldman JM, Melo JV. The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease. Blood. 1998;92:3362-3367.
2. Biernaux C, Loos M, Sels A, Huez G, Stryckmans P. Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals. Blood. 1995;86:3118-3122.
3. Bedi A, Zehnbauer BA, Barber JP, Sharkis SJ, Jones RJ. Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia. Blood. 1994;83:2038- 2044.
4. Shteper PJ, Ben-Yehuda D. Molecular evolution of chronic myeloid leukaemia. Semin Cancer Biol. 2001;11:313-323.
5. Jiang X, Lopez A, HolyoakeT, Eaves A, Eaves C. Autocrine production and action of IL-3 and granulocyte colony-stimulating factor in chronic myeloid leukemia. Proc Natl Acad Sci U S A. 1999;96:12804-12809.
6. Just U, Spooncer E, Lohler J, Stocking C, Ostertag W, Dexter TM. Mutants of a multipotent hematopoietic cell line blocked in GM-CSF-in- duced differentiation are leukemogenic in vivo.
7. Exp Hematol. 1994;22:933-940.
8. Zhang X, Ren R. Bcr-Abl efficiently induces a my- eloproliferative disease and production of excess interleukin-3 and granulocyte-macrophage colony-stimulating factor in mice: a novel model for chronic myelogenous leukemia. Blood. 1998; 92:3829-3840.
9. Xu B, Tian H, Zhou SY. Detection of FLT3 gene and FLT3/ITD gene mutation in chronic myeloid
10. leukemia and its significance. Ai Zheng. 2004;23: 1218-1221.
11. Mangan JK, Reddy EP. Activation of the Jak3 pathway and myeloid differentiation. Leuk Lymphoma. 2005;46:21-27.
12. Rane SG, Mangan JK, Amanullah A, et al. Activation of the Jak3 pathway is associated with granu- locytic differentiation of myeloid precursor cells. Blood. 2002;100:2753-2762.
13. Wetzler M, Kurzrock R, Estrov Z, et al. Altered levels of interleukin-1 β and interleukin-1 receptor antagonist in chronic myelogenous leukemia: clinical and prognostic correlates. Blood. 1994; 84:3142-3147.
14. Legros L, Bourcier C, Jacquel A, et al. Imatinib mesylate (STI571) decreases the vascular endo- thelial growth factor plasma concentration in patients with chronic myeloid leukemia. Blood. 2004;104:495-501.
15. Kvasnicka HM, Thiele J, Staib P, et al. Reversal of bone marrow angiogenesis in chronic myeloid leukemia following imatinib mesylate (STI571) therapy. Blood. 2004;103:3549-3551.
16. Korkolopoulou P, Viniou N, Kavantzas N, et al. Clinicopathologic correlations of bone marrow angiogenesis in chronic myeloid leukemia: a mor- phometric study. Leukemia. 2003;17:89-97.
17. Michelutti A, Michieli M, Damiani D, et al. Overex- pression of MDR-related p170 glycoprotein in chronic myeloid leukemia. Haematologica. 1994; 79:200-204.
18. TurkinaAG, Baryshnikov AY, Sedyakhina NP, et al. Studies of P-glycoprotein in chronic myelog- enous leukaemia patients: expression, activity and correlations with CD34 antigen. Br J Haema- tol. 1996;92:88-96.
19. Giles FJ, Kantarjian HM, Cortes J, et al. Multidrug resistance protein expression in chronic myeloid leukemia: associations and significance. Cancer. 1999;86:805-813.
20. + cells and is inhibited by imatinib mesylate. Blood. 2006;108: 1370-1373.
21. Yamagami T, Sugiyama H, Inoue K, et al. Growth inhibition of human leukemic cells by WT1 (Wilms tumor gene) antisense oligodeoxynucleotides: implications for the involvement of WT1 in leuke- mogenesis. Blood. 1996;87:2878-2884.
22. Moon HW, Kim TY, Oh BR, et al. MTHFR 677CC/ 1298CC genotypes are highly associated with chronic myelogenous leukemia: a case-control study in Korea. Leuk Res. 2007;31:1213-1217.
23. Ma X, Ruan G, Wang Y, et al. Two single-nucleo- tide polymorphisms with linkage disequilibrium in the human programmed cell death 5 gene 5′ regulatory region affect promoter activity and the susceptibility of chronic myelogenous leukemia in Chinese population. Clin Cancer Res. 2005;11: 8592-8599.
24. Hishida A, Terakura S, Emi N, et al. GSTT1 and GSTM1 deletions, NQO1 C609T polymorphism and risk of chronic myelogenous leukemia in Japanese. Asian Pac J Cancer Prev. 2005;6:251- 255.
25. Puil L, Liu J, Gish G, et al. Bcr-Abl oncoproteins bind directly to activators of the Ras signalling pathway. Embo J. 1994;13:764-773.
26. Bedi A, Griffin CA, Barber JP, et al. Growth factor- mediated terminal differentiation of chronic my- eloid leukemia. Cancer Res. 1994;54:5535-5538.
27. Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromo some. Science. 1990;247:824-830.
28. Elefanty AG, Hariharan IK, Cory S. bcr-abl, the hallmark of chronic myeloid leukaemia in man, induces multiple haemopoietic neoplasms in mice. EMBO J. 1990;9:1069-1078.
29. Kelliher MA, McLaughlin J, Witte ON, Rosenberg N. Induction of a chronic myelogenous leukemialike syndrome in mice with v-abl and BCR/ABL. Proc Natl Acad Sci USA. 1990;87:6649-6653.
30. Gishizky ML, Johnson-White J, Witte ON. Efficient transplantation of BCR-ABL-induced chronic myelogenous leukemia-like syndrome in mice. Proc Natl Acad Sci USA. 1993;90:3755-3759.
31. Pear WS, Miller JP, Xu L, et al. Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210
32. bcr/abl-transduced bone marrow. Blood. 1998;92:3780-3792.
33. Jaiswal S, Traver D, Miyamoto T, Akashi K, Lagasse E, Weissman IL. Expression of BCR/ ABL and BCL-2 in myeloid progenitors leads to myeloid leukemias. Proc Natl Acad Sci U S A.
34. 2003;100:10002-10007.
35. Era T, Witte ON. Regulated expression of P210 Bcr-Abl during embryonic stem cell differentiation stimulates multipotential progenitor expansion and myeloid cell fate. Proc Natl Acad Sci U S A. 2000;97:1737-1742.
36. Huettner CS, Zhang P, Van Etten RA, Tenen DG. Reversibility of acute B-cell leukaemia induced by BCR-ABL1. Nat Genet. 2000;24:57-60.
37. Nunez G, London L, Hockenbery D, Alexander M, McKearn JP, Korsmeyer SJ. Deregulated Bcl-2 gene expression selectively prolongs survival of growth factor-deprived hemopoietic cell lines.
38. J Immunol. 1990;144:3602-3610.
39. Salomoni P, Condorelli F, Sweeney SM,
40. Calabretta B. Versatility of BCR/ABL-expressing leukemic cells in circumventing proapoptotic BAD effects. Blood. 2000;96:676-684.
41. Sanchez-Garcia I, Grutz G. Tumorigenic activity of the BCR-ABL oncogenes is mediated by BCL2. Proc Natl Acad Sci USA. 1995;92:5287-5291.
42. Cambier N, Chopra R, Strasser A, Metcalf D, ElefantyAG. BCR-ABL activates pathways mediating cytokine independence and protection against apoptosis in murine hematopoietic cells in a dose-dependent manner. Oncogene. 1998;16: 335-348.
43. Delia D, Aiello A, Soligo D, et al. bcl-2 proto-oncogene expression in normal and neoplastic human myeloid cells. Blood. 1992;79:1291-1298.
44. Wei Y, Stockelberg D, Hullberg S, Ricksten A, Wadenvik H. Changes in expression of apoptosis-related genes are linked to the molecular response to imatinib treatment in chronic-phase chronic myeloid leukemia patients. Acta Haematol. 2007;117:83-90.